Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Sociologist Alex Rushforth (Nuffield Department of Primary Care Health Sciences), recently attended Oxford’s annual digital health pitching event, The Hill, for the first time. Here’s what he made of it.

Last month, a crowd composed largely of medical technology enthusiasts in the Oxfordshire area converged on Oxford University's Andrew Wiles Building for the annual digital health technology showcase, The Hill.

For those of you who are unfamiliar, the format of The Hill is reminiscent of TV shows like X-Factor and (especially) Dragon’s Den. 30 presenters each have only one minute and one slide to pitch a health app or device they have been developing (as individuals or part of a team). Following each presentation, the floor is opened to cross-examination by judges selected from sectors including universities, NHS, and industry. At the end of it all, the audience is invited to vote online for the winner. Those voted in the top-three are awarded prizes of £1000, as well as a period of one-to-one feedback from local technology consultants.  

Find out more (Nuffield Department of Primary Care Health Sciences website)

Similar stories

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.

£100 million donation from Ineos to create new institute to fight antimicrobial resistance

Awards and Appointments General Innovation

A new state of the art institute for antimicrobial research is to open at Oxford University thanks to a £100 million donation from Ineos.

University spinout PepGen awarded major financing to target Duchenne muscular dystrophy

Awards and Appointments General Innovation

PepGen, a therapeutics company targeting severe neuromuscular diseases, including Duchenne muscular dystrophy (DMD), has closed a $45 million Series A funding round led by RA Capital Management with participation from Oxford Sciences Innovation (OSI), the company’s original seed investor.

Evox Therapeutics announces launch of strategic collaboration with the University of Oxford

General Innovation

Collaboration with world-renowned research centre to accelerate development of exosome therapies for rare diseases

BioEscalator’s resident biotech Base Genomics acquired by Exact Sciences

General Innovation

Oxford Sciences Innovation (OSI) recently announced the acquisition of its portfolio company, Base Genomics, by US-based early cancer diagnostic leaders, Exact Sciences, for $410m. The partnership will enable Base Genomics to significantly accelerate its clinical and commercial development here in Oxford, potentially unlocking a new era of preventative medicine and improved patient outcomes.